By Iain Gilbert
Date: Tuesday 07 Oct 2025
(Sharecast News) - Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site in Rockville, Maryland, from ABL for $60m in cash, expanding its US footprint and strengthening its contract development and manufacturing offering.
Acquisition of US viral vector facility | 07-Oct-2025 | 07:00 | RNS |
Total Voting Rights | 01-Oct-2025 | 07:00 | RNS |
Interim Results for 6 months ended 30 June 2025 | 23-Sep-2025 | 07:00 | RNS |
Total Voting Rights | 01-Sep-2025 | 07:00 | RNS |
PDMR Dealings | 22-Aug-2025 | 15:36 | RNS |
Need to know: Opec cuts forecast ... Tesco cuts ... | 16-Aug-2008 | Times |
Need to know | 10-May-2008 | Times |
DSG International may be losing its spark | 12-Feb-2008 | Telegraph |
Oxford BioMedica clinches $690m licensing deal f... | 29-Mar-2007 | The Independent |
Oxford Biomedica seals €518m deal with Sanofi ov... | 29-Mar-2007 | Times |
No recent information was found.
Currency | UK Pounds |
Share Price | 648.00p |
Closing Price Change | 22.00p |
% Change | 0.00 % |
52 Week High | 655.00 |
52 Week Low | 232.50 |
Volume | 0 |
Shares Issued | 120.21m |
Beta | 0.03 |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
14:32 | 60 @ 650.00p |
14:31 | 70 @ 649.00p |
14:31 | 101 @ 649.00p |
14:31 | 1 @ 649.00p |
14:31 | 101 @ 650.00p |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research